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Use of B-lymphocyte (CD19D) Count as a Guide to Adjust the Doses of
Rituximab Infusion in Paediatric Patients
Wun Fung Hui
Queen Elizabeth Hospital, Hong Kong
Introduction: Rituximab is a chimeric murine /human monoclonal antibody
which has emerged as a novel therapy for various glomerular diseases in
Children. The optimal doses remain uncertain. We presented our experience
by monitoring the B-lymphocyte (CD19+) subset count as a guide to adjust
the dose of rituximab infusion. This indicator helps to avoid over-immunosup-
pression and to optimize the duration of B-lymphocyte (CD19+) depletion.
Case Summaries: Patient 1: A 10-year-old boy had been diagnosed with steroid-
dependent nephrotic syndrome since 2 years of age and was resistant to cyclo-
phosphamide therapy. His nephrotic syndrome remitted with cyclosporin A but
with frequent relapses.Renalbiopsyconfirmedfocalsegmentalglomerulosclero-
sis. He had serious complications of steroid and became tacrolimus dependent.
Two doses of rituximab infusion (375 mg/m2) were given weekly. Depletion of
B-lymphocyte (CD19+) was achieved after the 2nd dose of rituximab. His protein-
uria improvedandhis steroidwasweanedoff 5monthsafter rituximab (Figure 1).
Patient 2: A 16-year-old girl was diagnosed with systemic lupus erythematosus
at 6 years of age. She had class III lupus nephritis diagnosed at 11 years old and
was given a course of oral cyclophosphamide, followed by maintenance
azathioprine and prednisolone. Mycophenolate mofetil and tacrolimus were
added for recurrent relapses and uncontrolled disease. Two doses of rituximab
infusion 500 mg (375 mg/m2) were given weekly. She achieved better disease
control with B-lymphocyte (CD19+) depletion which lasted for 4 months. Pred-
nisolone was tapered to 7 mg daily. She experienced another relapse with
nephrotic range proteinuria 9 months later. Another two doses of rituximab
were given with good response. B-lymphocyte (CD19+) depletion lasted for
another 10 weeks (Figure 2) and her prednisolone was reduced to 5 mg daily.Figure 1. CD19+ count and urine protein / creatinine ratio after rituximab
infusion of patient 1.Figure 2: CD19+ count and urine protein / creatinine ratio after rituximab
infusion of patient 2.Conclusion: Two doses of rituximab can successfully deplete B-lymphocyte
(CD19+). Monitoring of B-lymphocyte (CD19+) counts helps to adjust the
dose of rituximab so as to prolong the duration of lymphocyte subset
depletion.http://dx.doi.org/10.1016/j.hkjn.2015.08.137
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“Late” is the Most Prominent Feature and Risk Factor for Patients with
Late-onset Lupus Nephritis
Na Tian, Wei Chen, Qian Zhou, Ling Yao Hong, Qi Mei Luo, Xue Qing Yu
Sun Yat-Sen University, GuangZhou, China
Objective: To distinguish the clinical and pathological characteristic of late-
onset lupus nephritis (LN) patients and their prognosis.
Methods: This is a retrospective cohort study. Patients who were diagnosed
as LN with age  14 from January 1st 1996 to December 31st 2011 were
enrolled. Baseline clinical characteristics and pathological information
were compared between late-onset group (LG) (onset age of LN  50) and
the control group (CG) (onset age of LN < 50), while the patient survival
and renal outcome (definded as serum creatinine doubled or ESRD) were fol-
lowed-up.
Results: Totally, 1264 patients were enrolled, with102 cases in LG and
1162 cases in CG. (1) The male to female ratio of LG was 2:5, doubling
to the CG (P Z 0.001). Patients in LG had more complications, higher sys-
tolic blood pressure and worse renal function (median eGFR: 59.59 vs
104.9 ml/min, P< 0.001). Patients with late-onset LN had a higher inci-
dence of AKI (27.5% vs 16.5%, P Z 0.005). No difference was shown on ac-
tivity index of SLE between the two groups. The renal pathological
comparisons indicated that chronic lesions of the LG were much more con-
spicuous than the CG, while the activity lesions of LN in two groups were
similar. (2) During the follow-up time of 55 (1, 207) months, 291 patients
reached the end-point, including 114 (13.1%) deaths, 107 (12.2%) creati-
nine doubled, and 80 (9.1%) ESRD. Kaplan-Meier curves showed that 5-
year and 10-year survival rates of LG were 68.5% and 49.1%, respectively,
much lower than that of the CG (P< 0.001). Patients in the LG had a worse
renal survival compared to CG (log rank Z 0.849, P Z 0.008). The older
onset-age was an independent risk factor for LN patients survival after
adjusted for confounders (HR Z 3.034, P Z 0.005). Increased Scr at base-
line was independently associated with renal survival while 1.1 mg/dL-
increment of Scr would lead to the hazard ratio of renal disfunction
increasing by 45% (P< 0.001).
Conclusion: The worse renal outcome of late-onset LN patients was more
likely to be associated with the decline renal function with aging than the
activity of SLE itself.http://dx.doi.org/10.1016/j.hkjn.2015.08.138
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Clinicopathological Characteristics and Outcomes in Male Patients with
Lupus Nephritis
Liping Xiong, Na Tian, Linyao Hong, Wang Zhang, Wei Chen, Xueqing Yu
Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen
University, Guangzhou, China
Objective: Long-term outcome of lupus nephritis (LN) in male patients is a
controversial issue. The objective is to evaluate clinicopathological charac-
teristics as well as renal and patient survival in male patients with lupus
nephritis.
Methods: All patients who fulfilled American College of Rheumatology lupus
Criteria were enrolled in the study. Clinicalpathological data of lupus
nephritis patients with different gender were retrospectively analyzed and
compared. Kaplan-Meier analysis and the Cox proportional hazards models
were used to evaluate the risk factors associated with renal and patient sur-
vival in male lupus nephritis patients.
Results: A total of 1272 lupus nephritis patients were enrolled, with a
mean age of 31.3  13.4 years. Among them, 215 were male and 1057
were female. Clinical presentation was similar except that males had a
significantly lower proportion of alopecia, arthralgia and leucocytopenia,
S54 Lupus Nephropathybut tended to present a higher prevalence of fever, acute kidney injury,
oliguria or anuria. During a median follow-up of 55.0 months, 107
(12.2%) patients had doubling of serum creatinine or ESRD (male 7.9% vs
female 8.5%) and 114 (13.0%) patients died (male 14.9% vs female 7.8%).
Regarding patient survival, compared with female patients, males had
no difference in renal outcome but had significantly higher mortality
than females.
Conclusion: The male lupus nephritis patients had worse renal function
compared with female patients. Moreover, male patients had significantly
higher mortality.http://dx.doi.org/10.1016/j.hkjn.2015.08.139
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The Role of Interaction Between Renal Proximal Tubular Epithelial Cells
and T Lymphocytes in the Pathogenesis of Tubulointerstial
Inflammation in Lupus Nephritis
D. Y. H. Yap, S. Yung, T. M. Chan
The University of Hong Kong, Hong Kong
Background: Renal proximal tubular epithelial cells (PTEC) and T lympho-
cytes assume pathogenic roles in tubulointerstitial inflammation in lupus
nephritis (LN). Their interaction in such inflammatory process remains
unclear.
Methods: CD4+ and CD8+ T cells were isolated from LN patients with (Group
I) or without (Group II) moderate to severe tubulointerstitial inflammation,
and co-incubated with PTEC in a transwell system. The level of cytokines
in the culture media were measured after 72 hours of co-culture and
compared between Group I and II patients.
Results: Twelve proliferative LN patients with (Group I; n Z 7) or without
(Group II; n Z 5) moderate to severe tubulointerstitial inflammation were
included. Group I patients showed significantly higher levels of RANTES
(p Z 0.002, 0.015 and 0.014) but lower IL-10 (p Z 0.018, 0.015 and 0.022)
when PTEC were co-cultured with their CD4+ T cells, CD8+ T cells or with
both CD4+ and CD8+ T cells. Group I also demonstrated higher levels of
MCP-1 (p Z 0.016 and 0.042) when PTEC were co-cultured with their CD8+
T cells or with both CD4+ and CD8+ T cells. There is no statistically significant
difference in IL-6 or IL-8, although Group I showed numerically much higher
IL-6 levels.
Conclusion: A significant increase in RANTES and MCP-1 and a decrease in IL-
10 levels were observed upon PTEC/T cell interaction in LN patients with
moderate to severe tubulointerstitial inflammation, and hence suggest the
putative roles of these cytokines in mediating tubulointerstitial inflamma-
tion in LN.http://dx.doi.org/10.1016/j.hkjn.2015.08.140
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Risk Factors of Renal Relapse in the Era of Effective Immunosuppressive
Treatments Among Chinese Lupus Nephritis Patients
D. Y. H. Yap, T. M. Chan
The University of Hong Kong, Hong Kong
Objective: Repeated renal flares jeopardize the long-term kidney function
in lupus nephritis (LN) patients. This study investigated the risk factors for
relapse in the era of effective immunosuppressive treatments.
Methods: All LN patients who were followed up in Queen Mary Hospital dur-
ing the period of 1 January 1983 to 31 December 2013 were reviewed. Epi-
sodes of renal relapses were identified and the risk factors for relapse
were analyzed. The risk of relapse was also analyzed according to the era
before (1983e1997) and after (1998e2013) the availability of mycophenolic
acid (MPA) treatment in our centre.Results: A total of 346 episodes of renal flares occurred in 184 patients (mean
follow-up duration 195.3  94.4 months). Multivariate analysis showed that
age (OR 0.97; 95% CI 0.943e0.998; pZ 0.038), higher serum creatinine on pre-
sentation (OR 0.992; 95% CI 0.985e0.999; PZ 0.019),use of mycophenolic acid
(MPA) as maintenance treatment (OR 0.322; 95% CI 0.0109e0.953; PZ 0.041)
and achievement of complete remission after induction therapy (OR 0.394;
95% CI 0.175e0.886; PZ 0.024) were factors associated with lower risk of renal
relapse. The choice of induction therapy, proteinuria and serological parame-
ters on presentation did not affect the risk of subsequent flares (all P> 0.05).
Rates of renal relapse were 0.044 and 0.024 relapse per patient-year before
and after the availability of MPA treatment (P< 0.001). Patients who received
prednisolone and MPA maintenance showed better relapse-free survival those
on prednisolone and azathioprine (AZA) (83% vs. 68%, 66% vs. 42% and 62% vs.
37% at 5, 10 and 15 years; PZ 0.048).
Conclusion: The risk of renal flare was low in the era of effective immuno-
suppressive treatments. The use of MPA as maintenance treatment might
have contributed to lower risk of LN relapse and appeared to be more effec-
tive than AZA to prevent flares.http://dx.doi.org/10.1016/j.hkjn.2015.08.141
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Variation and Clinical Significance of Circulation Annexin II in Patients
with Systemic Lupus Erythematosus
H. K. Hu, L. G. Y. Lu
The First Affiliated Hospital of Soochow University, Suzhou, China
Objective: To compare the level of annexin II in patients with systemic lupus
erythematosus, diabetic nephropathy, chronic glomerulonephritis and in
normal control group, to explore the significance of the annexin II in sys-
temic lupus erythematosus.
Methods: Thirty-five cases of patients with systemic lupus erythematosus,
10 cases of patients with diabetic nephropathy, and 10 cases of patients
with chronic glomerulonephritis were enrolled in this study; 20 cases of
healthy controls were also enrolled. Circulating annexin II in white blood
cells was detected by flow cytometry. Student’s t test, variance analysis
and linear correlation analysis were used for statistics.
Results: Compared with healthy control cases, the level of annexin II in
white blood cells in SLE patients (7.10  2.89%) and DN patients
(7.95  3.72%) were significantly lower than that in healthy controls
(P< 0.01, P< 0.05). In the SLE group, the level of annexin II in patients
who were more active (SLEDAI  9) decreased more than in those who
were less active (SLEDAI < 9; P< 0.05). As for annexin II, a positive correla-
tion was found with serum albumin (rZ 0.439, p< 0.01), negtive correlation
was found with urine protein/urine creatinine (r Z 0.382, p< 0.05), SLE-
DAI (r Z 0.417, p< 0.05), and D-dimer (r Z 0.336, p< 0.05).
Conclusion: The level of annexin II is decreased in patients with systemic
lupus erythematosus. It can be used as a reflection of the abnormality of
the coagulation and fibrinolytic systems. It may be used as a good indicator
of the prothrombotic state in SLE patients, and be helpful in judging the ac-
tivity and therapeutic effect of the disease.http://dx.doi.org/10.1016/j.hkjn.2015.08.142
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Effect of Rituximab on Serum Levels of Anti-C1q Antibodies and
Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus
Nephritis
Xiaozhou Hu, Jin Zhang, Zhangzheng Zhao, Shaoting Wang
5th Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Objectives: To analyze and compare the effects of rituximab (RTX) and
cyclophosphamide (CTX) on the serum levels of anti-C1q antibodies and
